Patient perspectives when switching from Cosopt&reg; (dorzolamide-timolol) to Azarga&trade; (brinzolamide-timolol) for glaucoma requiring multiple drug therapy

Código QR

Patient perspectives when switching from Cosopt&reg; (dorzolamide-timolol) to Azarga&trade; (brinzolamide-timolol) for glaucoma requiring multiple drug therapy

Graham Anthony Auger, Mathew Raynor, Simon LongstaffOphthalmology Department, Royal Hallamshire Hospital, Sheffield, South Yorkshire, United KingdomBackground: This study aimed to determine the impact of switching patients requiring multiple drug treatment from the dorzolamide-timolol fixed combinat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Auger GA, Raynor M, Longstaff S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/ce063d03e5b740d8a156a13fe9af5b82
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A patient preference comparison of Azarga&trade; (brinzolamide/timolol fixed combination) vs Cosopt&reg; (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension
por: Thomas K Mundorf, et al.
Publicado: (2008)

Tolerability and effectiveness of preservative-free dorzolamide&ndash;timolol (preservative-free Cosopt&reg;) in patients with open-angle glaucoma or ocular hypertension
por: Cindy Hutnik, et al.
Publicado: (2010)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension
por: Sanseau A, et al.
Publicado: (2013)

Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
por: Altafini R, et al.
Publicado: (2015)

Rational use of the fixed combination of dorzolamide &ndash; timolol in the management of raised intraocular pressure and glaucoma
por: Jason Yeh, et al.
Publicado: (2008)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
por: Inoue K, et al.
Publicado: (2015)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Miguel A Teus, et al.
Publicado: (2009)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
por: Shimizu Y, et al.
Publicado: (2015)

Effect of dorzolamide/timolol combination on the visual field in glaucoma
por: Takeda S, et al.
Publicado: (2014)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension
por: Yoshikawa K, et al.
Publicado: (2014)

Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
por: Moisseiev E,&nbsp;Lazar M, et al.
Publicado: (2012)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension [Erratum]
por: Yoshikawa K, et al.
Publicado: (2014)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Antoine Lafuma, et al.
Publicado: (2011)

Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
por: Lo JS, et al.
Publicado: (2016)

Brinzolamide-timolol suspension: acceptability and side effect profile
por: Doherty MD, et al.
Publicado: (2011)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Kanamoto T, et al.
Publicado: (2012)

Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension
por: Syed MF, et al.
Publicado: (2011)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
por: Lerner SF, et al.
Publicado: (2019)

Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops
por: Myungjin Kim, et al.
Publicado: (2021)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
por: Lorenz K, et al.
Publicado: (2011)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Dur&aacute;n LM, et al.
Publicado: (2012)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
por: Nicholas P Bell, et al.
Publicado: (2010)

Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension
por: Nagayama M, et al.
Publicado: (2014)

Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination
por: Contreras-Salinas H, et al.
Publicado: (2021)

Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
por: Henny JM Beckers, et al.
Publicado: (2009)

Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients
por: Makoto Ishikawa, et al.
Publicado: (2009)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
por: Mizoguchi T, et al.
Publicado: (2011)

Phase III safety and efficacy study of long-term brinzolamide/timolol fixed combination in Japanese patients with open-angle glaucoma or ocular hypertension
por: Nakajima M, et al.
Publicado: (2013)

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
por: Jordão MLS, et al.
Publicado: (2014)

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
por: Yoshimi Nakamura, et al.
Publicado: (2009)

Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure
por: Takeda S, et al.
Publicado: (2014)

Preliminary results following the use of a fixed combination of timolol&ndash;brimonidine in patients with ocular hypertension and primary open-angle glaucoma
por: Dimitris Papaconstantinou, et al.
Publicado: (2009)

Switching from concomitant therapy to tafluprost/timolol fixed combination
por: Inoue K, et al.
Publicado: (2018)

The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma
por: Nakamoto K, et al.
Publicado: (2018)

The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
por: Radcliffe NM
Publicado: (2014)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Moataz E Gheith, et al.
Publicado: (2008)

Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost
por: Fechtner RD, et al.
Publicado: (2011)

Bevacizumab (Avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma
por: Dimitrios Brouzas, et al.
Publicado: (2009)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
por: Kozobolis V, et al.
Publicado: (2018)

Comparison of ultra-widefield fluorescein angiography with the Heidelberg Spectralis&reg; noncontact ultra-widefield module versus the Optos&reg; Optomap&reg;
por: Witmer MT, et al.
Publicado: (2013)